In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Obesity therapies and the multi-indication momentum: how industry is responding
The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their potential across a spectrum of interconnected conditions. New data reveals how the breakthrough has sparked a major shift toward multi-indication drug development.
-
Hot shots: The power and potential of study tokenisation for vaccine research and post-commercialisation
Discover how clinical trial tokenisation helps sponsors gain patient insights and enable long-term data collection—without adding burden to patients or sites.
-
The impact of drug pricing and reimbursement on the pharmaceutical industry
Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. Companies must consider price and reimbursement across multiple countries, act early in the development cycle and ensure the evidence required to support their commercial strategy is built into their development plans.
-
ICON launches multi-indication trial design service for obesity drugs
Clinical trial designs for obesity treatments should accommodate candidate drugs that have the potential to treat multiple conditions, or developers risk missing opportunities, according to Irish CRO ICON.
-
More efficient next-gen obesity clinical trials needed, says survey
In this DDW article, discover key findings of an ICON survey focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
ICON retains lead as most active CRO in Q1, reveals Global Data.
ICON maintains its place as the most active contract research organization (CRO) for Q1 2025.
-
Pharma giants eye obesity trial boom — but are they ready for what comes next?
ICON survey shows pharma's enthusiasm for multi-indication obesity trials is outpacing trial design readiness.
-
Shifting paradigms of clinical trial design accelerate CNS R&D
Meeting the demand for clinically relevant neurodegenerative treatments requires a paradigm shift in how central nervous system (CNS) clinical trials have been designed and executed. Bill Holt outlines how drug developers are now at the forefront of adopting more nuanced, cost-effective, and patient-centric clinical trial designs.
-
Shaping tomorrow: Today’s leaders are building a stronger, more inclusive future for the industry
In this article, Rose Kidd, President of Operational Delivery, discusses how greater support for women in leadership and research is helping to shape a stronger future for the pharma industry.
-
Clinical strategies to optimize software as a medical device to treat mental health
Every clinical trial has challenges, but trials researching SaMD use to treat mental health disorders have unique ethical, regulatory and technical ones. In this Applied Clinical Trials article ICON’s Devin Ridgley and JoAnne Bronikowski explore the implications of a vulnerable patient population and new technology.
